RxDoctor Payments Data

Paul Lopez, MD

Internal Medicine · Colton, CANPI 1902357734

Payments from drug & device makers

$2,365in general payments, 2019–2025

Across 187 payments — averaging $12.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$396
  • Pfizer$352
  • Lilly USA, LLC$334
  • Boehringer Ingelheim$312
  • Corcept Therapeutics$307
  • Novo Nordisk$230
  • plus $434 from 7 others

What the payments were for

  • Food & beverage$2,365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,365 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$144,196
Medicare patients
194
Services billed
1,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin746$662,227
TrulicityDulaglutide364$363,304
MounjaroTirzepatide211$208,452
KerendiaFinerenone122$117,682
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog120$32,142
XareltoRivaroxaban36$31,408
EliquisApixaban24$30,546
EntrestoSacubitril/Valsartan30$27,943
OzempicSemaglutide26$24,824
Bicillin L-APenicillin G Benzathine14$22,300
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$21,203
SteglatroErtugliflozin Pidolate48$17,606
Albuterol Sulfate HfaAlbuterol Sulfate317$12,860
Qvar RedihalerBeclomethasone Dipropionate43$11,954
Atorvastatin Calcium1,534$10,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$312$662,227746 claims
Lilly USA, LLCTrulicity, Mounjaro$334$571,756575 claims
BayerKerendia$396$117,682122 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$19$36,27364 claims
PfizerEliquis$352$30,54624 claims
Novo NordiskOzempic$230$24,82426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Colton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →